$GHSI
Guardion Health Sciences Inc

2024 Q3 Form 10-Q Financial Statement

#000149315224031604 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $72.92K
YoY Change -97.39%
Cost Of Revenue $36.57K
YoY Change -97.63%
Gross Profit $36.35K
YoY Change -97.09%
Gross Profit Margin 49.85%
Selling, General & Admin $1.404M
YoY Change -35.74%
% of Gross Profit 3862.35%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $4.570K
YoY Change -5.38%
% of Gross Profit 12.57%
Operating Expenses $1.418M
YoY Change -37.32%
Operating Profit -$1.381M
YoY Change 36.41%
Interest Expense -$751.7K
YoY Change -886.79%
% of Operating Profit
Other Income/Expense, Net -$751.7K
YoY Change 370.5%
Pretax Income -$2.133M
YoY Change 81.94%
Income Tax
% Of Pretax Income
Net Earnings $10.32M
YoY Change -980.61%
Net Earnings / Revenue 14158.82%
Basic Earnings Per Share $8.04
Diluted Earnings Per Share $7.96
COMMON SHARES
Basic Shares Outstanding 1.284M shares 1.284M shares
Diluted Shares Outstanding 1.298M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.82M
YoY Change 77.09%
Cash & Equivalents $14.82M
Short-Term Investments
Other Short-Term Assets $378.9K
YoY Change -62.11%
Inventory $77.80K
Prepaid Expenses
Receivables $12.73K
Other Receivables $0.00
Total Short-Term Assets $15.29M
YoY Change 13.86%
LONG-TERM ASSETS
Property, Plant & Equipment $6.654K
YoY Change -84.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $6.654K
YoY Change -84.54%
TOTAL ASSETS
Total Short-Term Assets $15.29M
Total Long-Term Assets $6.654K
Total Assets $15.30M
YoY Change 13.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $113.4K
YoY Change -88.49%
Accrued Expenses $796.6K
YoY Change 76.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $917.3K
YoY Change -54.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $631.3K
YoY Change -85.11%
Total Long-Term Liabilities $631.3K
YoY Change -85.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $917.3K
Total Long-Term Liabilities $631.3K
Total Liabilities $1.549M
YoY Change -75.16%
SHAREHOLDERS EQUITY
Retained Earnings -$87.99M
YoY Change -6.76%
Common Stock $1.284K
YoY Change 1.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.75M
YoY Change
Total Liabilities & Shareholders Equity $15.30M
YoY Change 13.54%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $10.32M
YoY Change -980.61%
Depreciation, Depletion And Amortization $4.570K
YoY Change -5.38%
Cash From Operating Activities -$1.080M
YoY Change 165.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $16.25M
YoY Change
Cash From Investing Activities $16.25M
YoY Change -759445.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.952M
YoY Change
NET CHANGE
Cash From Operating Activities -1.080M
Cash From Investing Activities 16.25M
Cash From Financing Activities -5.952M
Net Change In Cash 9.218M
YoY Change -2355.72%
FREE CASH FLOW
Cash From Operating Activities -$1.080M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001642375
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38861
dei Entity Registrant Name
EntityRegistrantName
GUARDION HEALTH SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4428421
dei Entity Address Address Line1
EntityAddressAddressLine1
2925 Richmond Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1200
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77098
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
873-5141
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
GHSI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1284156 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14822826 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6359646 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12734 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9322 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
77797 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
97644 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
378892 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
562565 usd
CY2024Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
usd
CY2023Q4 GHSI Warrant Redemption Payable
WarrantRedemptionPayable
usd
CY2024Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2023Q2 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
usd
CY2023Q2 GHSI Cost Related To Settlement Of Placement Agent Warrants
CostRelatedToSettlementOfPlacementAgentWarrants
usd
GHSI Cost Related To Settlement Of Placement Agent Warrants
CostRelatedToSettlementOfPlacementAgentWarrants
usd
CY2023Q2 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
usd
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
usd
CY2024Q1 GHSI Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
usd
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
GHSI Cost Related To Settlement Of Placement Agent Warrants
CostRelatedToSettlementOfPlacementAgentWarrants
usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
GHSI Proceeds From Sale Of Discontinued Operations
ProceedsFromSaleOfDiscontinuedOperations
usd
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
GHSI Noncash Warrant Redemption Payable
NoncashWarrantRedemptionPayable
usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Research And Development
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
usd
CY2023Q2 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2023Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
4855755 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
15292249 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
11884932 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6654 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33245 usd
CY2024Q2 us-gaap Assets
Assets
15298903 usd
CY2023Q4 us-gaap Assets
Assets
11918177 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
113412 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22496 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
796590 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
499104 usd
CY2024Q2 GHSI Warrant Redemption Payable
WarrantRedemptionPayable
7325 usd
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
797434 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
917327 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1319034 usd
CY2024Q2 GHSI Warrant Derivative Liability Non Current
WarrantDerivativeLiabilityNonCurrent
631254 usd
CY2023Q4 GHSI Warrant Derivative Liability Non Current
WarrantDerivativeLiabilityNonCurrent
2453100 usd
CY2024Q2 us-gaap Liabilities
Liabilities
1548581 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3772134 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1284156 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1284156 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1275238 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1275238 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1284 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1275 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101737719 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101711035 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-87988681 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93566267 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
13750322 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8146043 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15298903 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11918177 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
72918 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
79633 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
154037 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
173874 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36572 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
86574 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
80738 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
155134 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
36346 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
-6941 usd
us-gaap Gross Profit
GrossProfit
73299 usd
us-gaap Gross Profit
GrossProfit
18740 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5183 usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8088 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7672 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11961 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
38547 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1395721 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1405771 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2826754 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3106585 usd
CY2024Q2 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-13863 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-17229 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1417672 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1413443 usd
us-gaap Operating Expenses
OperatingExpenses
2855944 usd
us-gaap Operating Expenses
OperatingExpenses
3150315 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1381326 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1420384 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2782645 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3131575 usd
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
549320 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
255300 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3817908 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1642800 usd
CY2024Q2 GHSI Cost Related To Settlement Of Placement Agent Warrants
CostRelatedToSettlementOfPlacementAgentWarrants
319625 usd
GHSI Cost Related To Settlement Of Placement Agent Warrants
CostRelatedToSettlementOfPlacementAgentWarrants
319625 usd
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
117245 usd
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
95534 usd
us-gaap Interest Income Other
InterestIncomeOther
192890 usd
us-gaap Interest Income Other
InterestIncomeOther
194533 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-751700 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-159766 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3944643 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1837333 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2133026 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1580150 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6727288 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1294242 usd
CY2024Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
200923 usd
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
463837 usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
578132 usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
798688 usd
CY2024Q2 GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
485952 usd
CY2023Q2 GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
56098 usd
GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
1015642 usd
GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
143766 usd
CY2024Q2 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
12742385 usd
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
12742385 usd
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
12457356 usd
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
407739 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
12304875 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
654922 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
10324330 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1172411 usd
us-gaap Net Income Loss
NetIncomeLoss
5577587 usd
us-gaap Net Income Loss
NetIncomeLoss
-639320 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.66
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.25
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-5.25
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.02
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
9.70
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.32
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
9.60
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.52
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.04
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1284156 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1267340 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1282241 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1267340 shares
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.64
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.25
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-5.22
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.02
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
9.60
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.32
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
9.54
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.52
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.96
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1297638 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1268103 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289566 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1268366 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8146043 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
12615 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
2170 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4746744 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3414085 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
9737 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
2170 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
10324330 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
13750322 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7917922 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
25182 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
5329 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
533091 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8481524 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8481524 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
-73456 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
5388 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1172411 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1172411 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7241045 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7241045 usd
us-gaap Net Income Loss
NetIncomeLoss
5577587 usd
us-gaap Net Income Loss
NetIncomeLoss
-639320 usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
578132 usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
798688 usd
GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
1015642 usd
GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
143766 usd
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
12742385 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6727288 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1294242 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
9361 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
9620 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-17229 usd
GHSI Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
22352 usd
GHSI Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
-48274 usd
GHSI Fair Value Of Vested Restricted Common Stock
FairValueOfVestedRestrictedCommonStock
4341 usd
GHSI Fair Value Of Vested Restricted Common Stock
FairValueOfVestedRestrictedCommonStock
10717 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3817908 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1642800 usd
GHSI Cost Related To Settlement Of Placement Agent Warrants
CostRelatedToSettlementOfPlacementAgentWarrants
319625 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3412 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-27 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-19847 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-119153 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-183673 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
205421 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
90916 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-65183 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3807 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
297486 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-89207 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1947962 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3209417 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
113196 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
923705 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1834766 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2285712 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3791 usd
GHSI Proceeds From Sale Of Discontinued Operations
ProceedsFromSaleOfDiscontinuedOperations
16250000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16250000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3791 usd
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
5952054 usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
5250000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5952054 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5250000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8463180 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7539503 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6359646 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15905490 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14822826 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8365987 usd
GHSI Noncash Warrant Redemption Payable
NoncashWarrantRedemptionPayable
7325 usd
CY2024Q2 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
17200000 usd
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-50
CY2023Q1 GHSI Minimum Closing Bid Price Value
MinimumClosingBidPriceValue
1.00
CY2023Q1 GHSI Minimum Closing Bid Price Value
MinimumClosingBidPriceValue
1.00
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
17200000 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
16250000 usd
us-gaap Net Income Loss
NetIncomeLoss
5577587 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
12304875 usd
GHSI Gain Loss On Sale Of Discontinued Operations
GainLossOnSaleOfDiscontinuedOperations
11726743 usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
578132 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1834766 usd
CY2024Q2 us-gaap Cash
Cash
14822826 usd
CY2024Q2 GHSI Working Capital
WorkingCapital
14374922 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zMi1F5wphLOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zawR4Qu4ByJ5">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q2 GHSI Third Party Outsourcing
ThirdPartyOutsourcing
26499 usd
CY2023Q2 GHSI Third Party Outsourcing
ThirdPartyOutsourcing
61809 usd
GHSI Third Party Outsourcing
ThirdPartyOutsourcing
64475 usd
GHSI Third Party Outsourcing
ThirdPartyOutsourcing
87309 usd
CY2024Q2 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2023Q2 us-gaap Advertising Expense
AdvertisingExpense
400 usd
us-gaap Advertising Expense
AdvertisingExpense
0 usd
us-gaap Advertising Expense
AdvertisingExpense
1657 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zVndQzM0pU4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zsG27Sa9o76d">Concentration of Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Vendor costs</i>. During the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">three months ended June 30, 2024, <span style="background-color: white">the Company utilized one vendor for its corporate legal advice. Costs associated with this vendor accounted for approximately <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_zZZ44RqNr41f" title="Concentration risk percentage">48</span>% of total costs during the three months ended June</span> 30, 2024, <span style="background-color: white">and approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_zgWjTs4Ea5g1" title="Concentration risk percentage">31</span>% of total costs during the three months ended June 30, 2023. One other vendor the Company used for insurance purposes accounted for approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneOtherVendorMember_znXjjHWjucgd" title="Concentration risk percentage">42</span>% of total costs during the three months ended June 30, 2023. </span>No other vendors accounted for more than 10% of total costs during the three months ended June 30, 2024 and 2023<span style="background-color: white">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Accounts payable</i>. As of June</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30, 2024<span style="background-color: white">, three vendors accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeVendorsMember_zgDsYVlRp6Xd" title="Concentration Risk, Percentage">75</span>% of total accounts payable. One vendor accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zI48ZO4yFJF8" title="Concentration Risk, Percentage">35</span>%, a second vendor accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondVendorMember_zrtCCrBPexY9" title="Concentration Risk, Percentage">27</span>% and a third vendor accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdVendorMember_zR6XVzGG3mJ9" title="Concentration Risk, Percentage">13</span>% of the accounts payable at June 30, 2024. As of </span>December 31, 2023, three <span style="background-color: white">vendors accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeVendorsMember_zC3PqQhEDKV6" title="Concentration Risk, Percentage">81</span>% of the total accounts payable. One vendor accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zgNHfrH6LmEd" title="Concentration Risk, Percentage">55</span>%, a second vendor accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondVendorMember_zCO1ocLeRu5e" title="Concentration Risk, Percentage">14</span>% and a third vendor accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdVendorMember_z88yLD8SCwTd" title="Concentration Risk, Percentage">12</span>% of the accounts payable at December 31, 2023. No other vendor accounted for more than 10% of accounts payable as of June</span> 30, 2024 <span style="background-color: white">and December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash and cash equivalents.</i> Cash and cash equivalents consist of funds deposited with BMO Harris Bank (“BMO”), a major, established, high quality financial institution in short-term (original maturity of generally 60 days or less) liquid investments in money market deposit accounts. Cash equivalents are classified as Level 1 in the GAAP valuation hierarchy and are valued using the net asset value (“NAV”) per share of the money market fund. The Company has an overnight investment feature established with BMO whereby the Company’s cash is swept into a Money Market Mutual Fund managed by Goldman Sachs Asset Management. This fund invests solely in high quality U.S. government issued securities. As of June 30, 2024, $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240630_ztSujFNoTAd5" title="Cash">14,822,826</span> included in cash and cash equivalents was held in the Goldman Sachs Financial Square Government Institutional Fund, a fund that is not insured by the Federal Deposit Insurance Corporation (the “FDIC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20240630_ztHavG4Jtrbc" title="Cash FDIC insured amount">250,000</span> and $<span id="xdx_900_ecustom--CashSIPCInsuredAmount_iI_c20240630_zdIfnNBB5NQ7" title="Cash SIPC insured amount">500,000</span>, respectively. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because of its assessment of the creditworthiness and financial viability of the financial institutions that hold such cash balances. The Company has not experienced any losses to date resulting from this policy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14822826 usd
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 GHSI Cash Sipc Insured Amount
CashSIPCInsuredAmount
500000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1284156 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1267340 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1297638 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1268103 shares
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
88240 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1549074 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1282241 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1267340 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289566 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1268366 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
91182 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1548808 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
91182 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1548808 shares
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
631254 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2453100 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2453100 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-3817908 usd
GHSI Fair Value Of Warrants Redeemed For Cash Settlement
FairValueOfWarrantsRedeemedForCashSettlement
-5632429 usd
GHSI Fair Value Of Warrant Redemption Payable
FairValueOfWarrantRedemptionPayable
-7325 usd
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
631254 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Base Purchase Price
DisposalGroupIncludingDiscontinuedOperationBasePurchasePrice
17200000 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Carrying Amount Of Net Assets Sold
DisposalGroupIncludingDiscontinuedOperationCarryingAmountOfNetAssetsSold
3732615 usd
GHSI Disposal Group Including Discontinued Operation Total Other Income Loss
DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeLoss
11726743 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
16250000 usd
GHSI Disposal Group Including Discontinued Operation Transaction Costs Paid At Closing
DisposalGroupIncludingDiscontinuedOperationTransactionCostsPaidAtClosing
725000 usd
CY2024Q2 us-gaap Escrow Deposit
EscrowDeposit
225000 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
225000 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Base Purchase Price
DisposalGroupIncludingDiscontinuedOperationBasePurchasePrice
17200000 usd
GHSI Disposal Group Including Discontinued Operation Base Purchase Price
DisposalGroupIncludingDiscontinuedOperationBasePurchasePrice
17200000 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Carrying Amount Of Net Assets Sold
DisposalGroupIncludingDiscontinuedOperationCarryingAmountOfNetAssetsSold
3732615 usd
GHSI Disposal Group Including Discontinued Operation Carrying Amount Of Net Assets Sold
DisposalGroupIncludingDiscontinuedOperationCarryingAmountOfNetAssetsSold
3732615 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Gain On Sale Before Transaction Costs
DisposalGroupIncludingDiscontinuedOperationGainOnSaleBeforeTransactionCosts
13467385 usd
GHSI Disposal Group Including Discontinued Operation Gain On Sale Before Transaction Costs
DisposalGroupIncludingDiscontinuedOperationGainOnSaleBeforeTransactionCosts
13467385 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Transaction Costs Paid At Closing
DisposalGroupIncludingDiscontinuedOperationTransactionCostsPaidAtClosing
725000 usd
GHSI Disposal Group Including Discontinued Operation Transaction Costs Paid At Closing
DisposalGroupIncludingDiscontinuedOperationTransactionCostsPaidAtClosing
725000 usd
CY2024Q2 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
12742385 usd
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
12742385 usd
CY2024Q2 GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
485952 usd
GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
1015642 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Total Other Income Loss
DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeLoss
12256433 usd
GHSI Disposal Group Including Discontinued Operation Total Other Income Loss
DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeLoss
11726743 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
1889472 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
2710184 usd
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
4807998 usd
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
5801631 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
1138504 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
1453976 usd
us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
2914982 usd
us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
3235803 usd
CY2023Q2 GHSI Disposal Group Including Discontinued Operation Research And Development
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
77200 usd
GHSI Disposal Group Including Discontinued Operation Research And Development
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
3168 usd
GHSI Disposal Group Including Discontinued Operation Research And Development
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
134750 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Sales And Marketing
DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing
330618 usd
CY2023Q2 GHSI Disposal Group Including Discontinued Operation Sales And Marketing
DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing
407408 usd
GHSI Disposal Group Including Discontinued Operation Sales And Marketing
DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing
688653 usd
GHSI Disposal Group Including Discontinued Operation Sales And Marketing
DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing
975189 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
219427 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
307763 usd
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
623063 usd
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
657201 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
200923 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
463837 usd
us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
578132 usd
us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
798688 usd
CY2024Q2 GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
485952 usd
CY2023Q2 GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
56098 usd
GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
1015642 usd
GHSI Transaction Costs Related To Sale Of Discontinued Operations
TransactionCostsRelatedToSaleOfDiscontinuedOperations
143766 usd
CY2024Q2 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
12742385 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
12742385 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Total Other Income Loss
DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeLoss
12256433 usd
CY2023Q2 GHSI Disposal Group Including Discontinued Operation Total Other Income Loss
DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeLoss
-56098 usd
GHSI Disposal Group Including Discontinued Operation Total Other Income Loss
DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeLoss
11726743 usd
GHSI Disposal Group Including Discontinued Operation Total Other Income Loss
DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeLoss
-143766 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Income From Discontinued Operations
DisposalGroupIncludingDiscontinuedOperationIncomeFromDiscontinuedOperations
12457356 usd
CY2023Q2 GHSI Disposal Group Including Discontinued Operation Income From Discontinued Operations
DisposalGroupIncludingDiscontinuedOperationIncomeFromDiscontinuedOperations
407739 usd
GHSI Disposal Group Including Discontinued Operation Income From Discontinued Operations
DisposalGroupIncludingDiscontinuedOperationIncomeFromDiscontinuedOperations
12304875 usd
GHSI Disposal Group Including Discontinued Operation Income From Discontinued Operations
DisposalGroupIncludingDiscontinuedOperationIncomeFromDiscontinuedOperations
654922 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
1912252 usd
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
2265072 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
2628194 usd
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
2579469 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
215753 usd
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
11214 usd
CY2024Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
4756199 usd
CY2023Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
4855755 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Accounts Payable Current
DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
900424 usd
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Payable Current
DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
591626 usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Accrued Liabilities Current
DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
123160 usd
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Accrued Liabilities Current
DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
205808 usd
CY2024Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1023584 usd
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
797434 usd
CY2024Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
3732615 usd
CY2023Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
4058321 usd
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
34400 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
35404 usd
CY2024Q2 us-gaap Inventory Finished Goods And Work In Process Net Of Reserves
InventoryFinishedGoodsAndWorkInProcessNetOfReserves
43397 usd
CY2023Q4 us-gaap Inventory Finished Goods And Work In Process Net Of Reserves
InventoryFinishedGoodsAndWorkInProcessNetOfReserves
62240 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
77797 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
97644 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
3000 usd
CY2024Q2 GHSI Fair Value Of Warrants Redeemed For Cash Settlement
FairValueOfWarrantsRedeemedForCashSettlement
5632429 usd
CY2024Q2 GHSI Cost Related To Settlement Of Placement Agent Warrants
CostRelatedToSettlementOfPlacementAgentWarrants
319625 usd
GHSI Cost Related To Settlement Of Placement Agent Warrants
CostRelatedToSettlementOfPlacementAgentWarrants
319625 usd
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
631254 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2453100 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
5250000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
4750000 usd
CY2023Q1 GHSI Proceeds From Issuance Of Private Placement Additional
ProceedsFromIssuanceOfPrivatePlacementAdditional
500000 usd
CY2023Q1 us-gaap Debt Instrument Redemption Price Percentage
DebtInstrumentRedemptionPricePercentage
1.05 pure
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1284156 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1284156 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1275238 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1275238 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
77930 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20577 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
77.72
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20577 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
77.72
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M20D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
14905 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
104.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M15D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20577 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
14905 shares
us-gaap Share Based Compensation
ShareBasedCompensation
22352 usd
us-gaap Share Based Compensation
ShareBasedCompensation
48273 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
5672 shares
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
37000 usd
GHSI Share Based Compensation Amortized Period
ShareBasedCompensationAmortizedPeriod
P1Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
10.04
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
46952 usd
CY2024Q2 GHSI Disposal Group Including Discontinued Operation Base Purchase Price
DisposalGroupIncludingDiscontinuedOperationBasePurchasePrice
17200000 usd
CY2024Q2 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
12742385 usd
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001493152-24-031604-index-headers.html Edgar Link pending
0001493152-24-031604-index.html Edgar Link pending
0001493152-24-031604.txt Edgar Link pending
0001493152-24-031604-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
ghsi-20240630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
ghsi-20240630_cal.xml Edgar Link unprocessable
ghsi-20240630_def.xml Edgar Link unprocessable
ghsi-20240630_lab.xml Edgar Link unprocessable
ghsi-20240630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending